Status:

COMPLETED

A Study in Participants With End-Stage Renal Disease

Lead Sponsor:

Eli Lilly and Company

Conditions:

Kidney Failure, Chronic

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this trial is to explore the effect of LY2127399 on those antibodies that are a barrier to kidney transplant. Transplantation is currently the definitive treatment for End-Stage Renal D...

Detailed Description

In this study, LY2127399 will be tested as a potential treatment to reduce the blood proteins in some participants with ESRD. These proteins are called alloantibodies and are made by the body to react...

Eligibility Criteria

Inclusion

  • Have ESRD and are awaiting kidney transplant
  • Have a stable PRA score \>50%

Exclusion

  • Have had a tonsillectomy
  • Have a semi-permanent/tunneled catheter
  • Have had intravenous immunoglobulin (IVIg) in the past 6 months
  • Have had plasmapheresis in the past 6 months
  • Uncontrolled hypertension
  • Presence of clinically significant cardiac disease in the past 6 months
  • Malignancy in the past 5 years, with the exception of cervical, basal cell and squamous epithelial cell cancers
  • Have active or recent infection including herpes zoster or herpes simplex in the last 30 days
  • Have evidence or suspicion of active Tuberculosis (TB)
  • Have had major surgery in the past 2 months
  • Have had a serious infection with recovery in the past 3 months
  • Have Hepatitis B or C or have Human Immunodeficiency Virus (HIV)

Key Trial Info

Start Date :

April 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2014

Estimated Enrollment :

18 Patients enrolled

Trial Details

Trial ID

NCT01200290

Start Date

April 1 2011

End Date

March 1 2014

Last Update

May 14 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Indianapolis, Indiana, United States, 46202